Dalton Pharma Services (Dalton) has expanded its pharmaceutical manufacturing services by adding formulation development to its list of integrated capabilities.
Reportedly, Dalton’s analytical, process and formulation scientists are equipped with technology and infrastructure to provide clients with the expertise required to move virtually all types of molecules from development to commercialisation in various types of dosage forms. Dosage forms include: sterile and non-sterile liquids, solids, semi-solids and lyophilized formulations (small chemical molecules, proteins and peptides, monoclonal antibodies and high-potency actives).
Peter Pekos, president and CEO of Dalton, said: “The addition of formulation services to our integrated pharmaceutical development capabilities allows us to offer complete drug development and manufacturing of novel pharmaceutical products. Our investment in state of the art capsule filling technology is one of many examples of how we respond to our clients’ needs.
“We have also expanded our Analytical Services to serve our formulation development experts and as a result now offer dissolution testing and particle size distribution testing in our FDA compliant, Health Canada approved analytical testing laboratories.”